Zynerba Pharmaceuticals Inc logo

ZYNE - Zynerba Pharmaceuticals Inc News Story

$4.92 0.1  2.3%

Last Trade - 21/02/20

Sector
Healthcare
Size
Small Cap
Market Cap £88.0m
Enterprise Value £28.2m
Revenue £66.3k
Position in Universe 4162nd / 6408

BRIEF-Zynerba Pharmaceuticals Q3 Loss Per Share $0.08

Wed 6th November, 2019 12:54pm
Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2019
FINANCIAL
RESULTS AND OPERATIONAL HIGHLIGHTS
    * Q3 LOSS PER SHARE $0.08
    * Q3 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES
DATA
    * PHASE 2 TOPLINE RESULTS IN AUTISM SPECTRUM DISORDER AND
22Q11.2
DELETION SYNDROME ON TRACK FOR 1H2020
    * TOPLINE RESULTS FROM PIVOTAL TRIAL IN FRAGILE X SYNDROME
ON
TRACK FOR 1H2020
    * COMPANY'S CASH AND CASH EQUIVALENT POSITION AS OF
SEPTEMBER 30,
2019 WAS $77.5 MILLION
    * CASH AND CASH EQUIVALENT POSITION AS OF SEPTEMBER 30, 2019
WAS
$77.5 MILLION
    * EXPECT TO ANNOUNCE TOPLINE RESULTS FOR CONNECT-FX TRIAL IN
FIRST
HALF OF NEXT YEAR
    * ZYNERBA- CASH & CASH EQUIVALENT SUFFICIENT TO FUND
OPERATIONS,CAPITAL REQUIREMENTS BEYOND EXPECTED NDA SUBMISSION,
POTENTIAL APPROVAL OF ZYGEL IN FXS
    * INTENDS TO MEET WITH FDA IN FIRST HALF OF 2020 TO DISCUSS
CLINICAL PATH FORWARD IN DEE
    * ZYNERBA PHARMACEUTICAL - EXPECTS TO SUBMIT ITS NDA FOR
ZYGEL IN
FXS TO U.S. FDA IN SECOND HALF OF 2020

Source text for Eikon:  ID:nGNX1dymW8 
Further company coverage:  ZYNE.O
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.